Berry-Kravis, E. M., Lindemann, L., Jønch, A. E., Apostol, G., Bear, M. F., Carpenter, R. L., . . . Jacquemont, S. (2018). Drug development for neurodevelopmental disorders: Lessons learned from fragile X syndrome. Nature reviews. Drug discovery, 17(4), 280. https://doi.org/10.1038/nrd.2017.221
Chicago-Zitierstil (17. Ausg.)Berry-Kravis, Elizabeth M., et al. "Drug Development for Neurodevelopmental Disorders: Lessons Learned from Fragile X Syndrome." Nature Reviews. Drug Discovery 17, no. 4 (2018): 280. https://doi.org/10.1038/nrd.2017.221.
MLA-Zitierstil (9. Ausg.)Berry-Kravis, Elizabeth M., et al. "Drug Development for Neurodevelopmental Disorders: Lessons Learned from Fragile X Syndrome." Nature Reviews. Drug Discovery, vol. 17, no. 4, 2018, p. 280, https://doi.org/10.1038/nrd.2017.221.